Psychedelics American DEA boosts psychedelic drug production quotas The agency increases production every year as domestic research demands escalate Rowan DunneJanuary 6, 2026
Psychedelics Woke Pharma and Swinburne U partner for Australia’s biggest psilocybin trial The AUD$5M study will involve about 160 participants and aims to help combat treatment-resistant depression Rowan DunneFebruary 1, 2023
International European Psychiatric Association aligns with PAREA: a multi-organization psychedelic partnership The new member organization consists of over 78,000 psychiatrists Rowan DunneOctober 17, 2022
Psychedelics Silo Pharma prepares pre-IND package for FDA on novel ketamine formulation Company will collaborate with Premier Consulting as regulatory partner and utilize Zylö Therapeutics Z-Pod technology Rowan DunneOctober 3, 2022
Canada PharmAla Biotech becomes first public company producing GMP MDMA Biotechnology organization will also supply LaNeo product to Australian research institute for clinical trial Rowan DunneAugust 22, 2022
Business Recent acquisitions help Numinus bolster revenue 240 per cent year-over-year Numinus' gross margin improved to 29.1 per cent during Q2 2022 following acquisitions of Mindspace Psychology Services Inc. and the Neurology Centre of Toronto Ryan GarnerApril 19, 2022
Medical and Pharmaceutical Delic Labs granted permission to study psychedelics including LSD, MDMA The Vancouver-based research lab aims to increase understanding of the medical applications of psychedelic compounds Ryan GarnerApril 15, 2022
Business Numinus approved to study ayahuasca and San Pedro in Canada Used in sacred traditions for centuries, the firm says research will bring their medicinal benefits to a larger audience Natalia Buendia CalvilloMarch 9, 2022
Business Numinus develops in-house tests to detect compounds in psychedelic mushrooms The methods will be available as part of third-party client services Nick LabaNovember 29, 2021
Legalization DEA proposes hiking Schedule I drug production for medical research After a spike in demand for research, the DEA is proposing increased quotas for controlled substances including MDMA, LSD, psilocybin and cannabis Natalia Buendia CalvilloOctober 18, 2021